Abstracts tagged "Systemic sclerosis"

Abstract Number: 0671 • ACR Convergence 2025
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
Francesca Romana Di Ciommo¹, Ashish Balar², Subhash Kulkarni³, Aidan K Strother², Michael Hughes⁴, Brian Skaug⁵, Maureen Mayes⁶, Shervin Assassi⁷, Ali Y Ayla² and Zsuzsanna McMahan⁸, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³BIDMC, Boston, MA, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁸UT Health Houston, Houston, TX
Background/Purpose: Cardiac manifestations significantly impact the prognosis of patients with systemic sclerosis (SSc), underscoring the need for early risk stratification. While gastrointestinal (GI) symptoms are…
Abstract Number: 0224 • ACR Convergence 2025
Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
John Hickernell¹ and Zineb Aouhab², ¹Loyola Univeristy Medical Center, Chicago, IL, ²Loyola University Medical Center, Oak Brook, IL
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) reduces mortality. The American College of Radiology, European Society of Cardiology/European Respiratory…
Abstract Number: 2501 • ACR Convergence 2025
Microvascular dysfunction contributes to hand bone deterioration in SSc patients
Rosanna Campitiello¹, Sabrina Paolino², Andrea Casabella³, Giulia Davoli², Elisa Caratto⁴, Emanuele Gotelli¹, Elvis Hysa⁵, Carmen Pizzorni², Vanessa Smith⁶, Alberto Sulli² and Maurizio Cutolo⁷, ¹University of Genoa, Genoa, Liguria, Italy, ²University of Genoa, Genova, Italy, ³IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁴Univeristy of Genoa, Alessandria, Italy, ⁵University of Genoa, Genoa, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷University of Genova, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by endothelial dysfunction, self-reactive immune response and progressive systemic fibrosis1. It is well established that…
Abstract Number: 2475 • ACR Convergence 2025
GERD Severity, Proton Pump Inhibitor Use, and Longitudinal Forced Vital Capacity in the CONQUER Registry
Carrie Richardson¹, Shervin Assassi², Flavia Castelino³, Lorinda Chung⁴, Luke Evnin⁵, Tracy Frech⁶, Jessica Gordon⁷, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin⁷, Dorota Lebiedz-Odrobina¹¹, Yiming Luo¹², Ashima Makol¹³, Maureen Mayes¹⁴, Zsuzsanna McMahan¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Nora Sandorfi¹⁸, Ami Shah⁹, Ankoor Shah¹⁹, Brian Skaug²⁰, Virginia Steen²¹, Elizabeth Volkmann²², Carleigh Zahn²³, John VanBuren¹¹ and Elana Bernstein²⁴, ¹Northwestern University, Chicago, IL, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³Massachusetts General Hospital, Boston, MA, ⁴Stanford University, Stanford, CA, ⁵Scleroderma Research Foundation, Brisbane, CA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Hospital for Special Surgery, New York, NY, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Utah, Salt Lake City, UT, ¹²Columbia University Irving Medical Center, New York, ¹³Mayo Clinic, Rochester, MN, ¹⁴UT Health Houston Division of Rheumatology, Houston, TX, ¹⁵UT Health Houston, Houston, TX, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern University, Chicago, ¹⁸University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ¹⁹Duke University, Durham, NC, ²⁰UTHealth Houston Division of Rheumatology, Houston, TX, ²¹Georgetown University School of Medicine, Washington, DC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴Columbia University Irving Medical Center, New York, NY
Background/Purpose: Gastroesophageal reflux disease may contribute to the progression of interstitial lung disease in systemic sclerosis (SSc). However, it is unclear whether reflux severity or…
Abstract Number: 1865 • ACR Convergence 2025
Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Hanlin Yin¹, Wanyi Lin², Zhangyi zhao¹, Chenhan Jia¹ and Liangjing Lu¹, ¹Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, Shanghai, China (People's Republic), ²Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China (People's Republic)
Background/Purpose: Antinuclear antibodies (ANA) are detected in over 95% of systemic sclerosis (SSc) patients. Compared to cutaneous subtype classification, autoantibody-based stratification more accurately predicts survival,…
Abstract Number: 1575 • ACR Convergence 2025
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Kevin Chevalier¹, Brigitte Bader-Meunier², Isabelle Kone-Paut³, Benjamin Torreau⁴, Marc Michel⁵, Bertrand Godeau⁵, Christian AGARD⁶, Thomas Papo⁷, Karim Sacré⁸, Raphaele Seror⁹, Xavier Mariette¹⁰, Cacoub Patrice¹¹, Ygal Benhamou¹², Mathilde Leclercq¹³, Cécile goujard¹⁴, Olivier Lambotte³, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Luc Mouthon²² and Benjamin Chaigne²², ¹Université Paris Cité, Montrouge, France, ²Necker hospital, Paris, France, ³Bicêtre hospital, Kremlin Bicêtre, France, ⁴Internal Medicine and Immunology, CHU Tours, Tours, France, ⁵Henri Mondor hospital, Créteil, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Bichat hospital, Paris, France, ⁸Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ¹¹Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹²Internal Medicine, CHU Rouen, Rouen, France, ¹³Rouen hospital, Rouen, France, ¹⁴Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is an entity defined by clinical features of differentiated connective tissue diseases (dCTD), such as systemic lupus erythematosus (SLE),…
Abstract Number: 1193 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Angela Chang¹, Navid Saleh¹, Alec Yu¹, Darya S. Jalaledin², Sabrina Hoa³, Robert Levy⁴, Jennifer Wilson⁵, Charles Poirier⁶, John Yee¹, James Choi¹, Océane Landon-Cardinal⁷, Hyein Kim⁸ and Kun Huang⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Université de Montréal, Saint-Lambert, QC, Canada, ³University of Montreal, Brossard, QC, Canada, ⁴University of British Columbia, Deerfield, IL, ⁵UBC, Vancouver, BC, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸The University of British Columbia, Vancouver, BC, Canada, ⁹University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0692 • ACR Convergence 2025
A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with no Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
Christopher Denton¹, Philip Yee², medha kanitkar³, Charlotte Clarke⁴, Saiam Ahmed⁴, Voon H. Ong³, Francesco Del Galdo⁵, John Pauling⁶, Marina Anderson⁷, Muditha Samaranayaka⁸, Michael Hughes⁹, Smita Bhat¹⁰, Bridget Griffiths¹¹, MAYA BUCH¹², David D'Cruz¹³, Ariane Herrick¹⁴, Madelon Vonk¹⁵, Nicholas Feemantle⁴ and Dehbi Hakim-Moulay⁴, ¹University College London, UK, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Leeds, Leeds, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷Lancaster University and NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom, ⁸Salford Royal Hospital, Salford, United Kingdom, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ¹⁰Ninewells Hospital Dundee, Dundee, Scotland, United Kingdom, ¹¹Ninewells Hospital Dundee, Newcastle, England, United Kingdom, ¹²UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ¹³Kings College London, London, United Kingdom, ¹⁴The University of Manchester, UK, Aberdeen, United Kingdom, ¹⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Mycophenolate mofetil (MMF) is recommended for skin in diffuse cutaneous (dc)SSc, and for lung fibrosis in SSc, but patients with limited cutaneous (lc)SSc are…
Abstract Number: 0641 • ACR Convergence 2025
Safety and efficacy of autologous CD19-CAR T-cell therapy in patients with autoimmune disease – data from the CASTLE Phase I/II basket study
Melanie Hagen¹, Andreas Wirsching¹, Fabian Müller², Soraya Kharboutli³, Christina Bergmann¹, Sebastian Böltz¹, Jule Taubmann⁴, Carlo Tur¹, Laura Bucci¹, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Louis Schuster⁴, Koray Tascilar⁴, Silvia Spoerl³, Ingrid Vasova³, Panagiotis Garantziotis¹, Daniel Aletaha⁵, Hans-Peter Kiener⁶, gerlando Natalello⁷, Franco Locatelli⁸, Maria Antonietta D'Agostino⁹, Aline Bozec¹, Linda Hanssens¹⁰, Dirk De Vries¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Medical University Vienna, Wien, Austria, ⁶Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁷Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁹Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁰Miltenyi Biomedicine, Bergisch Gladbach, Bergisch Gladbach, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: Engineered T cells expressing a chimeric antigen receptor (CAR) binding CD19 are powerful tools to deplete B-cells, representing an attractive therapy for severe autoimmune…
Abstract Number: 0046 • ACR Convergence 2025
Association of Genetic Variation in XIST and FTX with Susceptibility to Female-Biased Systemic Autoimmune Disease
Thomas Riley¹, Dana DiRenzo¹, Ellen Romich², Michael Levin³, Scott Damrauer³, Michael George¹, Montserrat Anguera¹, Joshua Baker¹ and Nikhil Jiwrajka¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Media, PA, ³University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: The mechanisms underlying female sex bias in autoimmune diseases remain unclear. Recent work has suggested that impaired maintenance of X-chromosome inactivation (XCI) in female…
Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Emily Glowienka¹, Sarah Nickolls², Kevin Coady¹, Eesha Kodi³, Ian Steinfield¹, Florence Wilson³, Alicia N. Pepper³, Svetlana I. Nihtyanova⁴, Roger A. Levy⁵ and Daniel Moldaver⁶, ¹Precision AQ, Boston, MA, ²GSK, Research & Development, Stevenage, United Kingdom, ³Precision AQ, Vancouver, BC, Canada, ⁴GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁵GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁶GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…
Abstract Number: 2474 • ACR Convergence 2025
Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Carlos Valera Ribera¹, JUAN JOSE ALEGRE SANCHO², Ivan Castellvi³, Marta Ibañez⁴ and Javier Narváez⁵, ¹Hospital Universitario Doctor Peset, València, Spain, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Anticentromere antibody (ACA)-positive interstitial lung disease (ILD) in systemic sclerosis (SSc) is traditionally considered less aggressive than anti-topoisomerase I (ATA)-positive ILD. However, its clinical…
Abstract Number: 1864 • ACR Convergence 2025
Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis
Giulio Forte¹, Vasiliki Liakouli¹, Alessia Salzillo², Mario Angeli³, Daniele Mauro¹, Antonio Ciancio¹, Barbara De Marino², Iacopo Panarese¹, Mario Faenza¹, roberto giacomelli⁴, Andreas Ramming⁵ and Francesco Ciccia⁶, ¹Università della Campania Luigi Vanvitelli, Naples, Italy, ²University of Campania L. Vanvitelli, Naples, Italy, ³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁴Università Campus Bio-Medico, Roma, Italy, ⁵Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…
Abstract Number: 1573 • ACR Convergence 2025
Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
Katherine van der Wouden¹, Georgy Gomon², Rachel Knevel², Michel Tsang-A-Sjoe³, Alexandre Voskuijl³ and Jeska de Vries-Bouwstra², ¹Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…

« Previous Page
1
…
3
4
5
6
7
…
56
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].